Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, Chiu H, Hong R, Grogan J, Javinal V, Yauch R, Irving B, Belvin M, Mellman I, Kim JM, Schmidt M. Lau J, et al. Among authors: cheung j. Nat Commun. 2017 Feb 21;8:14572. doi: 10.1038/ncomms14572. Nat Commun. 2017. PMID: 28220772 Free PMC article.
Role of PD-1 during effector CD8 T cell differentiation.
Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R. Ahn E, et al. Among authors: cheung j. Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13. Proc Natl Acad Sci U S A. 2018. PMID: 29654146 Free PMC article.
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, Totpal K, Chiu H, Wu Y, Comps-Agrar L, Leader AM, Merad M, Roose-Germa M, Warming S, Yan M, Kim JM, Rutz S, Mellman I. Oh SA, et al. Among authors: cheung j. Nat Cancer. 2020 Jul;1(7):681-691. doi: 10.1038/s43018-020-0075-x. Epub 2020 Jun 22. Nat Cancer. 2020. PMID: 35122038
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP, Clevenger TN, Burke KA, Yang B, MacDonald A, Cunningham D, Fox CP, Goy A, Gribben J, Nowakowski GS, Roschewski M, Vose JM, Vallurupalli A, Cheung J, Raymond A, Nuttall B, Stetson D, Dougherty BA, Schalkwijk S, Carnevalli LS, Willis B, Tao L, Harrington EA, Hamdy A, Izumi R, Pease JE, Frigault MM, Flinn I. Collins GP, et al. Among authors: cheung j. Leuk Lymphoma. 2021 Nov;62(11):2625-2636. doi: 10.1080/10428194.2021.1938027. Epub 2021 Jul 16. Leuk Lymphoma. 2021. PMID: 34269152 Clinical Trial.
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A. Alsadhan A, et al. Among authors: cheung j. Clin Cancer Res. 2020 Jun 15;26(12):2800-2809. doi: 10.1158/1078-0432.CCR-19-3505. Epub 2020 Feb 13. Clin Cancer Res. 2020. PMID: 32054731 Free PMC article. Clinical Trial.
1,773 results